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Tampere, Lahti, FinlandBackground and Aims: Self-expanding biodegradable biliary stents (BDBSs) have recently become available for
use in endoscopic retrograde cholangiography (ERC). The aim was to evaluate the effectiveness and safety of
novel BDBSs in iatrogenic cystic duct leaks and benign biliary strictures (BBSs).
Methods: Patients providing informed consent were recruited for the prospective study. Braided self-expanding
poly-dioxanone BDBSs were inserted using ERC during from 2014 to 2016. Repeated liver function tests and
magnetic resonance imaging were performed during follow-up. The main outcomes were treatment success
and adverse events.
Results: Thirteen patients, 5 women, median age 67 years (range, 43-79) underwent BDBS insertion for iatro-
genic cystic duct leak (n Z 7) or BBS (n Z 6). Stent insertion using ERC was successful in all cases. All bile leaks
were treated uneventfully with BDBSs. In BBSs, the clinical success rate of BDBS therapy was 83% in a median of
21 months of follow-up (range, 14-25). Early ERC-related adverse events included 1 cholangitis (8%) and 1 pancre-
atitis (8%), both in the stricture group. During the first 90 days, 23% of patients were readmitted for mild
cholangitis.
Conclusions: The short- and long-term safety of endoscopically inserted poly-dioxanone BDBSs was satisfac-
tory. The management of cystic duct leaks and benign distal common bile duct strictures was highly success-
ful. Episodes of mild cholangitis during stent indwelling seemed to be typical of BDBSs. The advantage of
BDBSs is the avoidance of repeated endoscopy for stent removal. (Clinical trial registration number:
NCT02353286.)2An endoscopic insertion device for biodegradable biliary
stents (BDBSs) compatible with standard duodenoscopes
has become available only recently (Fig. 1). BDBSs could
potentially achieve a patency and radial expansion force
resembling widely used fully covered self-expanding metal
stents (FCSEMSs) while saving the cost and burden of
repeated endoscopy for stent removal.1 The most
common biodegradable material for stent manufacturing
is currently synthetic polymer poly-dioxanone (Fig. 2); its
biocompatibility in human biliary environment is wellns: BBS, benign biliary stricture; BDBS, biodegradable biliary
endoscopic retrograde cholangiography; FCSEMS, fully
-expanding metal stent; MRI, magnetic resonance imaging.
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TROINTESTINAL ENDOSCOPY Volume 87, No. 4 : 2018established. Very similar material has been used in
absorbable polydioxanone sutures in surgery since the
1980s.3
The widest experience of clinical use of poly-dioxanone
BDBSs is from about 100 patients treated percutaneously
for refractory biliary strictures. In this study by Mauri
et al,4 the usefulness and safety of BDBSs were
demonstrated in a nearly 2-year follow-up with a stricture
resolution rate of over 80%. The case reports of these
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Figure 1. A braided 10-mm bore (60-mm length) self-expandable biode-
gradable poly-dioxanone biliary stent with golden radiopaque markers at
both ends in situ as used in the study (Ella CS, Hradec Králové, Czech
Republic). The stent was inserted across the papilla for treatment of post-
cholecystectomy leak of the cystic duct.
Figure 2. A, The endoscopic insertion device with a 10.5F shaft compat-
ible with the working channel of a standard duodenoscope. B, A braided
8-mm bore (80-mm length) self-expandable poly-dioxanone stent before it
is loaded into insertion device (Ella CS, Hradec Králové, Czech Republic).
TABLE 1. Demographics and data on stent insertion in 13 patients






Median age, y (range) 73.0 (46-79) 62.5 (43-73)
Sex, women 1 (14) 4 (67)
Median bile duct diameter
maximum (range)
9.0 (6-12) 13 (9-19)
Sphincterotomy performed 7 (100) 4 (67)
Stone or sludge extraction 2 (29) 2 (33)
Guidewire
Standard .035 3 (43) 2 (33)
Stiff shaft .035 4 (57) 4 (67)
Stent length
40 mm 5 (71) 1 (17)
60 mm 2 (29) 2 (33)
80 mm 0 3 (50)
Stent diameter
8 mm 6 (86) 6 (100)
10 mm 1 (14) 0
Values are n (%), unless otherwise defined.
Siiki et al Endoscopically inserted biodegradable biliary stentswith the novel insertion device further validated the
technical success of insertion and short-term safety in
endoscopic use.5,6 The aim of this study was to investigate
the clinical feasibility and effectiveness of endoscopically
inserted BDBSs in the treatment of postcholecystectomy
cystic duct leak and benign biliary stricture (BBS) in long-
term follow-up.www.giejournal.org VMETHODS
Altogether, 13 patients with either postcholecystec-
tomy cystic duct leak or BBS were prospectively recruited
between 2014 and 2016 at Tampere University Hospital,
Finland. Patients with surgically altered duodenal anatomy
or considered noncompliant with follow-up protocol or
incompatible with magnetic resonance imaging (MRI)
were not recruited. The diagnosis of bile leak was based
on clinical features, CT scan, and bilirubin content in drain
output. In BBSs malignancy was excluded with CT and
MRI scans, and at least 1 set of benign brush cytology
samples was taken during earlier ERC and plastic stent
insertion.
A standard duodenoscope (TJF-Q180V; Olympus,
Hamburg, Germany) with carbon dioxide insufflation was
used in ERC. The biliary duct was cannulated with a stan-
dard short guidewire and sphincterotome (Dreamtome
RX44; Boston Scientific Corp., Marlborough, Mass). A
braided self-expandable biodegradable poly-dioxanone
8- or 10-mm bore biliary stent with golden radiopaque
markers at both ends (Ella CS, Hradec Králové, Czech
Republic) was then inserted in the common bile duct
across the papilla (Figs. 1 and 2). The insertion device
(Fig. 2) with a 10.5F shaft, closely resembling the
devices currently used in FCSEMSs, was introduced over
a guidewire through the working channel of a
duodenoscope. None of the strictures was dilated at the
time of BDBS insertion.olume 87, No. 4 : 2018 GASTROINTESTINAL ENDOSCOPY 1133
Figure 3. A, Endoscopic retrograde cholangiography image of a 71-year-old woman with a benign distal common bile duct biliary stricture, presumably
secondary to earlier common bile duct stones. B, Fluoroscopy image after endoscopic insertion of a 40  8-mm self-expandable biodegradable biliary
stent with radiopaque markers at both ends covering the stricture.
Endoscopically inserted biodegradable biliary stents Siiki et alBoth groups underwent a similar follow-up protocol:
liver function tests at 1, 3, 9, and 12 months and MRI at
3, 6, and 12 months after BDBS insertion. Data on proced-
ures, adverse events, and long-term results were prospec-
tively recorded in the hospital database. At the end of
follow-up the digital hospital record was reviewed for any
unplanned admissions, changes in treatment strategy, or
treatment failures. Median follow-up time was 21 months
(range, 5-25.5). The primary outcome measure was clinical
success rate of stent treatment, defined by absence of un-
scheduled interventions, change in treatment strategy, or
stricture relapse during the follow-up time. Secondary
outcome measures were technical success of endoscopic
stent insertion, adverse events, or readmissions during
the 30- and 90-day period after insertion as well as during
the follow-up.
The Ethics Committee of Pirkanmaa Hospital District,
Finland approved the study protocol. Informed consent
was obtained from all patients for research use of
BDBSs. The study was registered in Clinicaltrials.gov
(NCT02353286) and was conducted according to the
Helsinki Declaration. Statistical analysis was performed
using SPSS Statistics version 22 (IBM Corp, Armonk,
NY). Categorical variables were compared using the c21134 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 4 : 2018or Fisher exact test and continuous variables using the
Mann-Whitney U test. Statistical significance was set at
P < .05.RESULTS
Data on 13 patients treated with BDBSs for postchole-
cystectomy bile leak or BBS are presented in Table 1.
Endoscopic stent insertion was successful in all cases
(Figs. 1 and 3). Data on clinical outcome, repeated MRIs,
and liver function tests from both groups are presented
in Table 2. One patient was lost from follow-up in each
group. In all patients during the first 30 days there were
altogether 4 readmissions (31%), of which 2 were for
pain after stent insertion, 1 (8%) for mild cholangitis, and
1 (8%) for mild post-ERC pancreatitis (Table 3). During
the first 90 days there were 3 (23%) readmissions for
mild cholangitis.
Postcholecystectomy bile leaks
In the leak group ERC with BDBS insertion was per-
formed at a median of 4 days (range, 3-8) from laparo-
scopic cholecystectomy. All except 1 patient had a nativewww.giejournal.org






ERC-related adverse events 30 days 0 2 (33%)
Readmission 30 days
Pain 0 2 (33%)
Acute cholangitis 0 1 (17%)
Post-ERC pancreatitis 0 1 (17%)
Other adverse events (not ERC related)* 1 (14%) 0
Readmission 90 days
Acute cholangitis 1 (14%) 2 (33%)
ERC, Endoscopic retrograde cholangiography.
*See text.






Median follow-up, mo (range) 21.0 (5-25) 21.5 (14-25)
Patients lost from follow-up 1 (14) 1 (17)
Treatment failure 0 1 (17)*
Liver function tests: normal values
1 mo 7 (100) 6 (100)
3 mo 7 (100) 6 (100)
6 mo 6 (86)y 6 (100)
9 mo 6 (86)y 5 (83)y
12 mo 6 (86)y 5 (83)y
Magnetic resonance imaging
3 mo 7 (100) 5 (83)
Stent in place 4 (57) 2 (33)
Stent not visible 2 (29) 1 (17)
Stent partially migrated 1 (14) 2 (33)
6 mo 6 (86)y 6 (100)
Stent in place 2 (29) 1 (17)
Stent not visible 4 (57) 5 (84)
12 mo 6 (86)y 5 (83)y
No stricture 6 (86) 5 (83)
Values are n (%), unless otherwise defined.
*Stricture relapse at 17 months after BDBS insertion.
yOne patient in each group lost from follow-up.
Siiki et al Endoscopically inserted biodegradable biliary stentspapilla. One cannulation was performed with a double-
guidewire technique with consequent insertion of a pro-
phylactic pancreatic stent. The external drain was removed
on median day 5 (range, 2-7) after stent insertion.
Endoscopic treatment was successful in all cases of post-
cholecystectomy leak of the cystic duct (Table 2). Two
patients (29%) had traces of stent still visible in MRI at
6 months (Table 2). One of these patients underwent
ERC for pancreatic duct stent placement for chronic
pancreatitis–related pancreatic duct stricture at 4 months,
where BDBS remnants were removed with grasping
forceps.
There were no 30-day ERC-related adverse events. One
patient (14%) had mild cholangitis during the first 90 days.
Additionally, 1 patient with severe comorbidities had an
episode of severe lower limb ischemia and septic infection
resulting in eventual multiorgan failure and death 4
months after BDBS insertion. This event was not consid-
ered to be ERC related (Table 3).
Benign biliary strictures
Two strictures (33%) were secondary to chronic pancre-
atitis. Others had distal common bile duct stricture of open
etiology. However, no patients had postoperative stricture,
sclerosing cholangitis, or autoimmune-associated disease.www.giejournal.org VFive patients (83%) had previous single plastic stents in
place.
With biodegradable stents stricture treatment was
successful in 83% (Table 2). In most patients (84%) the
stents were not visible at the 6-month MRI (Fig. 4).
There was 1 (17%) treatment failure during follow-up:
the patient previously treated with an FCSEMS developed
a stricture relapse at 17 months. In this case permanent
treatment with an FCSEMS was chosen instead of opera-
tion because of unacceptable anesthesiology risk.
Two patients had mild ERC-related adverse events: 1
cholangitis (17%) and 1 post-ERC pancreatitis (17%). Addi-
tionally, 2 patients (33%) were readmitted overnight for
pain after stent insertion (Table 3). During the first 90
days there were 2 readmissions for mild cholangitis (33%).DISCUSSION
This pilot study evaluated the long-term clinical utility of
endoscopically inserted BDBSs in postcholecystectomy
bile leaks and BBSs. The biocompatibility and degradation
profiles have been demonstrated in several studies.7-9
Furthermore, the largest study on BDBSs yielded an
encouraging long-term success rate of 82% in the percuta-
neous management of refractory postoperative or chronic
pancreatitis–related strictures.4 Our main result was that
the endoscopic insertion of BDBSs was highly successful,
and stents were not associated with an alarming rate of
adverse events. Long-term follow-up of up to 2 years re-
vealed no unexpected problems. Most importantly, the
clinical efficacy of stricture management was excellent.
With the novel insertion device, stent placement was
successful in all cases. As in the first case reports of endo-
scopic BDBS use,5,6 some stents had to be adjusted to the
proper location with grasping forceps or extraction
balloon. The factor limiting the endoscopic use of BDBSs
has been the lack of a proper insertion device fitting into
the working channel of a duodenoscope with controlledolume 87, No. 4 : 2018 GASTROINTESTINAL ENDOSCOPY 1135
Figure 4. A, The biodegradable stent is visible as a filling defect of the common bile duct in coronal T2 haste thick slab magnetic resonance imaging at
3.5 months after stent insertion (arrows). B, At 6 months the stent has degraded and is not visible in a similar sequence (star). C, At the 12-month
magnetic resonance imaging there are no signs of stricture relapse or secondary stent-associated changes. The common bile duct is blurry because of
overlapping right renal pelvis (2 stars).
Endoscopically inserted biodegradable biliary stents Siiki et alstent delivery and expansion in the bile duct. Further
improved types of BDBSs resembling the current smooth
insertion devices of FCSEMSs may well make insertion
easier. Degradation of BDBSs, which usually taking be-
tween 3 and 6 months, was similar to that reported
earlier.4,7,10 The radiologic appearance of the novel poly-
dioxanone BDBSs in MRI has not been studied before
(Fig. 3). In the present series neither radiologic visibility
or invisibility nor signs of stent migration at the 3- or
6-month follow-up MRI seemed to correlate with clinical
outcome. A previous study of the percutaneous use of
BDBSs reported clinically significant migration in 2% of
patients, suggesting that not all stent migrations neces-
sarily result in treatment failure.4
There were no unexpected adverse events related to
endoscopic use of BDBSs. The readmissions for abdominal
pain were probably because of gradual stent expansion
during the first days. Nearly one fourth of patients had a
mild cholangitis during the 3 months after stent insertion.
This may be because of slow degradation and defragmen-
tation of the stent intermittently blocking bile flow and
causing acute cholangitis. All episodes were self-limiting
and managed with brief antibiotic treatment. Possibly
characteristic of poly-dioxanone stent treatment, similar
findings, and rates of 26% cholangitis have been reported
earlier in series of percutaneous use of BDBSs.4 Although
our study was underpowered to re-evaluate it, the occur-
rence of acute cholangitis has been associated with treat-
ment failure of a stricture.4 Moreover, episodes of acute
cholangitis are also associated with traditional plastic
stents and FCSEMSs in up to 10% to 30% of cases.11,12
In postcholecystectomy bile leak, the clinical success
rate of BDBS treatment was expectedly outstanding. In a1136 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 4 : 2018simple postcholecystectomy cystic duct leak, as in all the
current cases, conventional management with external
drain followed by endoscopic sphincterotomy and inser-
tion of a single plastic stent is usually unproblematic.13 In
a single animal study comparing plastic stents and 8-mm
bore BDBSs, the BDBS was associated with faster bile
leak resolution, presumably because of a larger stent diam-
eter and better downstream bile flow.14 When BDBSs are
used, a second endoscopy to remove the plastic stent
can be avoided, possibly balancing the inevitably higher
cost of the stent.
In BBSs long-term success rate of BDBSs was over 80%.
This is identical to the results of an earlier study, where
stricture recurrence occurred in 18% of BBS patients
when BDBSs were inserted percutaneously.4 Two thirds
of our strictures were benign distal common bile duct
stenoses that could probably have been successfully
treated with FCSEMSs. The remaining third was
secondary to chronic pancreatitis, often poorly resistant
to any method of endoscopic treatment, except long-
term FCSEMS use.15 The only treatment failure was in a
patient whose previous treatment with FCSEMSs had
failed because of stent migration. As with bile leaks, the
main advantage of BDBSs over FCSEMSs in BBS could
be the avoidance of stent removal. Contrary to silicone-
covered FCSEMSs, biodegradable stents could also be
used across the hilar region or cystic duct confluence.
Furthermore, an accidentally long indwelling time, for
example, because of poor patient compliance in alcohol-
related chronic pancreatitis, could be avoided with
BDBSs.
Our study supports the current view of the safety and
good biocompatibility of biodegradable materials in humanwww.giejournal.org
Siiki et al Endoscopically inserted biodegradable biliary stentsbiliary environment.2,3,7-9 Previously in the esophagus,
poly-dioxanone stents have been associated with second-
ary epithelial hyperplasia and strictures.16 Such a
potential hazard must also be borne in mind in future
studies on BDBSs in the biliary duct. However, we
perceived no adverse foreign body reaction leading to
clinical consequences or MRI findings in our patients.
This is in line with animal studies, where the tissue
reaction of BDBSs is reportedly temporary and does not
differ from epithelial reaction caused by plastic stents
even in blinded histologic analysis.7,14 The only study
comparing the reaction of biliary epithelium to BDBSs or
FCSEMSs suggested that expression of proteins associated
with tissue healing is different and potentially closer to
intact bile duct after BDBS indwelling.17 In addition, the
study by Mauri et al4 reported no secondary
biodegradable stent–related strictures or hyperplasia in
the long follow-up of 107 patients.
The strength of the study is the long follow-up time of
nearly 2 years, during which recurrences or stent-related
problems, such as secondary strictures because of epithe-
lial hyperplasia, may appear. Additionally, the meticulous
surveillance with repeated liver function tests and repeated
MRIs during the first year after stent insertion was conduct-
ed to record in detail all radiologic and clinical treatment
failures and adverse events. All our patients were from
the catchment area of a single surgical emergency depart-
ment, making us confident of capturing all readmissions or
unscheduled visits. The small numbers of patients, the
dropout rate, and absence of control groups with conven-
tional treatment are the major weaknesses. Moreover, we
used mostly 8-mm bore stents, whereas those with
10-mm bore apparently yield better clinical results in
BBSs.4 Further product updates of the stent insertion
device may overcome the challenges with the old-
generation device we used. It may therefore be premature
to draw firm conclusions on the clinical efficacy of BDBSs
in endoscopic stricture management.
In summary, novel self-expanding poly-dioxanone
BDBSs may be safely used even in ERC. The clinical feasi-
bility and safety as well as long-term patency were
confirmed in follow-up lasting up to 2 years. There were
no unexpected adverse events. The surveillance with
repeated MRI during the first year revealed the anticipated
degradation pattern.www.giejournal.org VREFERENCES
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